; and (2) by adding at the end the following new subparagraph: (J) Reporting on additional committees with formulary decision making authority (i) In general For 2026 and each subsequent plan year, a PDP sponsor shall submit to the Secretary the following information, if applicable, with respect to each prescription drug plan offered by the PDP sponsor: (I) The name and a description of the role and composition of any committee, entity, or individual within or affiliated with the PDP sponsor (or a pharmacy benefit manager, acting under contract with such sponsor) that has the authority to make a coverage, formulary placement, or utilization management decision (as defined in clause (ii)(I)), other than the pharmacy and therapeutic committee described in subparagraph (A). (II) A list of drugs for which a committee, entity, or individual described in subclause (I) made a coverage, formulary placement, or utilization management decision (as so defined) and the corresponding initial recommendation (as defined in clause (ii)(II)) made by the pharmacy and therapeutic committee. (III) A brief justification for each decision described in subclause (II). (ii) Definitions In this subparagraph: (I) Coverage, formulary placement, or utilization management decision The term coverage, formulary placement, or utilization management decision means a decision by a committee, entity, or individual described in clause (i)(I) that modifies, adjusts, reverses, or otherwise alters (such as by substituting the formulary inclusion of one covered part D drug for another or by substituting a more general initial recommendation for a more specific decision) an initial recommendation by the pharmacy and therapeutic committee. (II) Initial recommendation The term initial recommendation means a coverage, formulary placement, or utilization management decision recommended by the pharmacy and therapeutic committee prior to the review, adoption, or modification of such a recommendation by a committee, entity, or individual described in clause